Incidence and oncologic outcomes of patients with prostate‐specific antigen persistence after radical prostatectomy
One in eight patients who undergo prostatectomy experience PPP. These patients constitute a unique, high-risk population distinct from patients who have NED and BCR. Clinical trials addressing optimal treatment and intensity for these at-risk patients are critically warranted.
Authors
- Jason Hafron (ORCID: https://orcid.org/0000-0003-0866-797X)
- Patrick Lewicki (ORCID: https://orcid.org/0000-0002-0692-2909)
- Robert Timothy Dess (ORCID: https://orcid.org/0000-0003-2331-3758)
- James D. Montie
- Archana Radhakrishnan (ORCID: https://orcid.org/0000-0001-7689-6390)
- Sabir Meah (ORCID: https://orcid.org/0009-0006-4101-3221)
- Corinne Labardee
- Khurshid R. Ghani (ORCID: https://orcid.org/0000-0002-3944-9759)
- Brian R. Lane
- Kevin B Ginsburg
- Sabrina L. Noyes
- Stephanie Daignault‐Newton
- Tudor Borza
Institutions
- Grand Rapids Community College (US)
- Oakland University (US)
- Wayne State University (US)
- University of Michigan (US)
- Orthopaedic Associates of Michigan (US)
- Michigan Institute of Urology (US)
- Royal Oak Community Coalition (US)
- Michigan State University (US)
Publication Details
- Journal
- Cancer
- Published
- 2026-02-05
- DOI
- https://doi.org/10.1002/cncr.70291
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00